Clinical features and treatment results in preterm infants with intracardiac thrombus

J Matern Fetal Neonatal Med. 2021 Jun;34(11):1763-1767. doi: 10.1080/14767058.2019.1647530. Epub 2019 Jul 31.


Introduction: Thrombus incidence is higher among neonates, especially in preterm infants, due to the associated additional risk factors.

Materials and methods: The medical recordings of premature infants who had been diagnosed as having intracardiac thrombus between January 2016 and January 2019 were evaluated retrospectively. We use recombinant tissue plasminogen activator when the thrombus is relatively large compared to left atrium, pedunculated, mobile, or snake shaped.

Results: A total of 13 premature patients were diagnosed as having intracardiac thrombus during the 3-year period. All were diagnosed during echocardiographic studies. Low molecular weight heparin was administered in four patients. In three, recombinant tissue plasminogen activator was started with low dose (0.01 mg/kg/h) and increased gradually to 0.06 mg/kg/h. In three, recombinant tissue plasminogen activators were started with standard dose (0.5 mg/kg/h). In one recombinant tissue, plasminogen activator was started with low dose (0.01 mg/kg/h) and increased to standard dose. Two patients died before treatment, three patients died during treatment, follow-up was not available for two patients, and thrombus completely resolved in six patients.

Discussion: In preterm babies with risk factors, intracardiac thrombus should be kept in mind during all echocardiographic studies. In our patients, low and standard dose regimens were used, and the treatment results were similar.

Keywords: Intracardiac thrombus; preterm infants; recombinant tissue plasminogen activator.

MeSH terms

  • Fibrinolytic Agents
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • Retrospective Studies
  • Thrombosis* / diagnostic imaging
  • Thrombosis* / drug therapy
  • Tissue Plasminogen Activator*


  • Fibrinolytic Agents
  • Tissue Plasminogen Activator